Skip to main content
. Author manuscript; available in PMC: 2012 May 18.
Published in final edited form as: Cancer. 2008 Mar 1;112(5):1114–1121. doi: 10.1002/cncr.23282

FIGURE 1.

FIGURE 1

Comparison of hazard ratios for gefitinib versus placebo in patients with epidermal growth factor receptor (EGFR)-positive versus -negative tumor samples with various cutoff points to define positivity with the Dako EGFR PharmDx kit and percentage of cells with positive staining.